Institutional investors hold a majority ownership of IMGN through the 94.27% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended June 2016, these large investors purchased a net $4.5 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
RENAISSANCE TECHNOLOGIES LLC Bought 2.0 Million shares of ImmunoGen Inc
MILLENNIUM MANAGEMENT LLC Bought 1.6 Million shares of ImmunoGen Inc
MORGAN STANLEY & CO. LLC Bought 1.5 Million shares of ImmunoGen Inc